Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

Core Insights - Zevra Therapeutics has presented new data on MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium, highlighting its long-term safety and effectiveness in both pediatric and adult patients [1][2] Company Overview - Zevra Therapeutics, Inc. is a commercial-stage company focused on therapies for rare diseases, with MIPLYFFA being its lead product approved by the U.S. FDA on September 20, 2024 [5][18] - The company aims to provide meaningful therapies for patients with rare diseases and is expanding access through geographic opportunities [18] Product Information - MIPLYFFA (arimoclomol) enhances the activation of transcription factors, leading to the upregulation of lysosomal expression and regulation genes, and has shown to reduce unesterified cholesterol in NPC fibroblasts [5] - The pivotal phase 3 trial demonstrated that MIPLYFFA halted disease progression compared to placebo over one year, as measured by the NPC Clinical Severity Scale [5] Clinical Data Highlights - Real-world data from the U.S. Early Access Program (EAP) over four years indicate that arimoclomol was well tolerated and stabilized disease progression, with clinical severity scores remaining below thresholds for meaningful worsening [6] - Long-term evidence supports durable treatment effects of arimoclomol, showing sustained clinical benefits with continued use [6] - A post hoc analysis of the NPC002 trial indicated that arimoclomol combined with miglustat significantly slowed disease progression as early as three months after treatment initiation [6] - The four-year dataset from adult NPC patients treated in the U.S. EAP provides robust insights into the treatment's impact on this understudied population [6][7] Regulatory Status - MIPLYFFA has received Orphan Medicinal Product designation from the European Medicines Agency (EMA) for the treatment of NPC, and a Marketing Authorization Application has been submitted for evaluation [5][7]